Reply letter to "safety of SARS-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance"

Hum Vaccin Immunother. 2021 Nov 2;17(11):4115-4116. doi: 10.1080/21645515.2021.1959149. Epub 2021 Sep 2.

Abstract

In the letter, Urro et al. performed a search on the sucrose, fructose and sorbitol content in the approved Sars-Cov-2 vaccines and they concluded that these vaccines can be safely administered in adults affected by Hereditary fructose intolerance.The Pfizer-BioNTech COVID-19 Vaccine is currently approved for use in adolescents ≥ 12 years and the Moderna COVID-19 vaccine is close to approval for use in children over 12 years of age. Furthermore, both vaccines have initiated clinical trials that will include infant as young as 6 months. Therefore, we considerate important to analyze the safely administration of this two vaccines in children with Hereditary fructose intolerance.

Keywords: SARS-Cov 2; vaccine; Hereditary fructose intolerance; children; sucrose.

Publication types

  • Letter
  • Comment

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273
  • Adolescent
  • Adult
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Child
  • Fructose Intolerance*
  • Humans
  • Infant
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • 2019-nCoV Vaccine mRNA-1273
  • BNT162 Vaccine